Intensity Therapeutics (INTS) Change in Account Payables (2022 - 2023)
Intensity Therapeutics' (INTS) quarterly Change in Account Payables came in at -$1.2 million in Q3 2023, down 467.43% YoY from $332963.0 in Q3 2022, and down 467.43% on a QoQ basis from $332963.0 in Q3 2022.
Intensity Therapeutics (INTS) Change in Account Payables (2022 - 2023) Analysis & Trends
Intensity Therapeutics (INTS) has 2 years of Change in Account Payables data on file, last reported at -$1.2 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Intensity Therapeutics | 13.06 Mn | 13.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -1.22 Mn |
| Sep 30, 2023 | -1.22 Mn |
| Sep 30, 2022 | 332,963.00 |
| Sep 30, 2022 | 332,963.00 |